Skip to main content
. Author manuscript; available in PMC: 2020 Oct 22.
Published in final edited form as: Clin Cancer Res. 2017 Nov 14;24(4):744–752. doi: 10.1158/1078-0432.CCR-17-1590

Table 3.

Grade 3 and 4 Adverse Events* at Least Possibly Related to Therapy in the 51 Evaluable Patients (all cycles)

Toxicity Grade 3 Grade 4
Anemia 16 (31.3%) ---
Leukopenia 16 (31.3%) 3 (5.8%)
Neutropenia 10 (19.6%) 13 (22.8%)
Thrombocytopenia 9 (17.6%) 3 (5.8%)
Febrile Neutropenia 1(2.0%) ---
Sepsis --- 1 (2.0%)
Fatigue 1 (2.0%) ---
Nausea 1 (2.0%) ---
Hypokalemia 1 (2.0%) ---
*

As per NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0